Literature DB >> 35789790

Olfactory dysfunctions 6 months after a SARS-CoV-2 infection.

Pilar Quintana-Castro1, David Dylan Garcia-Melendez1, María Isabel Morales-Casado1.   

Abstract

Entities:  

Year:  2022        PMID: 35789790      PMCID: PMC9242720          DOI: 10.1016/j.medcle.2022.02.012

Source DB:  PubMed          Journal:  Med Clin (Engl Ed)        ISSN: 2387-0206


× No keyword cloud information.
Dear Editor: The medical sequelae of the 2019 coronavirus disease (COVID-19) have been described in multiple studies. These include some neurological symptoms, such as an altered sense of smell, which is reported by up to 50% of patients with this disease. In most patients, this symptom usually resolves two to four weeks after the infection, but this is not always the case and it may persist over time, having a significant impact on the patient’s long-term quality of life. In a cross-sectional study including 86 patients with hyposmia following a mild case of COVID-19 and not requiring hospitalization, 58 (67.44%) reported a subjective olfactory disturbance for over 6 months after recovering from the infection (mean of 389.50 days with hyposmia; standard deviation [SD] 117.33). The characteristics of this population are outlined in Table 1 below.
Table 1

Population characteristics.

Age, mean (SD)38.5 years (9.1)
Sex, n (%)Male8 (13.8)
Female50 (86.2)
Smoking habit, n (%)No33 (56.9)
Yes7 (12.1)
Ex-smoker >6 months18 (31.0)
Personal neurological history, n (%)No39 (67.2)
Headache15 (25.9)
Tremor1 (1.7)
Epilepsy1 (1.7)
Dizziness1 (1.7)
Sleep disorders1 (1.7)
Presence of allergy, n (%)24 (41)
Population characteristics. We conducted a clinical interview to collect variables such as the existence of parosmia (altered sense of smell), olfactory distortions in relation to food, presence of phantosmias (olfactory hallucinations), and symptoms related to brain fog. In addition, we performed a neurological physical examination and used Sniffin’ Sticks Olfactory Test, designed and validated to objectively assess olfactory capacity, consisting in presenting a patient with 16 sticks with odors that they must attempt to identify among four possible options. The hyposmia pattern described by most patients is striking, since, although it tends to reach its maximum degree within the first few days following the initial infection, most patients report an improvement after the second or third week, albeit with subsequent worsening that persists over the following months. Of the 58 patients suffering from subjective hyposmia for over six months, 43 had an objective pathological test, with the apple-scented stick being that linked to the highest rate of error, with approximately 77.6% of patients failing to recognize the smell. Most of the participants (more than 75%) reported having parosmias, mostly with unpleasant odors (cacosmias) in relation to food, this being a symptom that has previously also been described in other studies. It is noteworthy that, during the clinical interviews, many of these patients linked the parosmias to odors to which they had been exposed very frequently prior to developing COVID-19. To conclude, it should be noted that, although hyposmia is more common within the first weeks of a case of COVID-19 and in certain variants, the percentage of patients in whom this alteration persists in the long-term is not negligible. It is important to highlight the probable functional limitation and emotional impact that olfactory disturbances persisting for over 6 months after a case of COVID-19 could have on a person. This symptom, together with others already described in persistent COVID-19, such as brain fog, which are initially relegated to a secondary role during the acute infection, can interfere in a person’s daily life and persist in the long-term, with the consequent detriment to their quality of life. It would be interesting to propose new studies aimed at determining the longer-term evolution of this type of clinical manifestations, as well as to clarify the pathophysiology of these symptoms.

Funding

This study received no funding from any source.

Conflicts of interest

The authors of this paper declare no conflicts of interest in relation to this study.
  5 in total

1.  Prevalence and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients.

Authors:  J R Lechien; C M Chiesa-Estomba; E Beckers; V Mustin; M Ducarme; F Journe; A Marchant; L Jouffe; M R Barillari; G Cammaroto; M P Circiu; S Hans; S Saussez
Journal:  J Intern Med       Date:  2021-01-05       Impact factor: 8.989

2.  Frequency of Neurologic Manifestations in COVID-19: A Systematic Review and Meta-analysis.

Authors:  Shubham Misra; Kavitha Kolappa; Manya Prasad; Divya Radhakrishnan; Kiran T Thakur; Tom Solomon; Benedict Daniel Michael; Andrea Sylvia Winkler; Ettore Beghi; Alla Guekht; Carlos A Pardo; Greta Karen Wood; Sherry Hsiang-Yi Chou; Ericka L Fink; Erich Schmutzhard; Amir Kheradmand; Fan Kee Hoo; Amit Kumar; Animesh Das; Achal K Srivastava; Ayush Agarwal; Tarun Dua; Kameshwar Prasad
Journal:  Neurology       Date:  2021-10-11       Impact factor: 9.910

3.  Evaluation of Olfactory Function With Objective Tests in COVID-19-Positive Patients: A Cross-Sectional Study.

Authors:  E Deniz Gözen; Chinara Aliyeva; Fırat Tevetoğlu; Rıdvan Karaali; İlker İnanç Balkan; H Murat Yener; H Ahmet Özdoğan
Journal:  Ear Nose Throat J       Date:  2020-11-25       Impact factor: 1.697

4.  Long-term persistence of olfactory and gustatory disorders in COVID-19 patients.

Authors:  Nhu Ngoc Nguyen; Van Thuan Hoang; Jean-Christophe Lagier; Didier Raoult; Philippe Gautret
Journal:  Clin Microbiol Infect       Date:  2021-01-05       Impact factor: 8.067

Review 5.  Medical sequels of COVID-19.

Authors:  Francisco Pablo Peramo-Álvarez; Miguel Ángel López-Zúñiga; Miguel Ángel López-Ruz
Journal:  Med Clin (Barc)       Date:  2021-05-27       Impact factor: 1.725

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.